Mercer Global Advisors’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Mercer Global Advisors’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-2,699	Closed	-$16K	–	2116
2023 Q3	$16K	Hold	2,699	–	–	﹤0.01%	1931
2023 Q2	$19K	Sell	2,699 -40	-1%	-$264	﹤0.01%	1894
2023 Q1	$43K	Sell	2,739 -150	-5%	-$2.95K	﹤0.01%	1873
2022 Q4	$58K	Buy	2,889 +150	+5%	+$2.99K	﹤0.01%	1855
2022 Q3	$49K	Sell	2,739 -5	-0.2%	-$107	﹤0.01%	1771
2022 Q2	$61K	Buy	2,744 +192	+8%	+$4.28K	﹤0.01%	1761
2022 Q1	$71K	Buy	2,552 +40	+2%	+$1.46K	﹤0.01%	1817
2021 Q4	$114K	Buy	2,512 +5	+0.2%	+$336	﹤0.01%	1712
2021 Q3	$209K	Sell	2,507 -2,500	-50%	-$207K	﹤0.01%	1601
2021 Q2	$476K	Hold	5,007	–	–	﹤0.01%	1168
2021 Q1	$833K	Buy	+5,007	New	+$662K	0.01%	861

Other funds holding ONCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PPW

Pasadena Private Wealth Pasadena, California $723M AUM 18.72% 1-Year Est. Return

Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return

Mercer Global Advisors's ONCT Position: Q4 2023 in Review

Mercer Global Advisors sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2023, closing a stake of 2,699 shares — an estimated $16K sold.

Mercer Global Advisors first reported a position in ONCT in Q1 2021 and held it in 11 quarters. The position peaked at $833K in Q1 2021. 38 funds tracked by Wall St. Rank hold ONCT as of Q4 2023.

Mercer Global Advisors reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Mercer Global Advisors sold 2,699 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $16K.
Mercer Global Advisors first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q1 2021 and held it in 11 quarters.
Mercer Global Advisors's Oncternal Therapeutics, Inc. Common Stock position peaked at $833K in Q1 2021.
38 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Mercer Global Advisors's 13F filing for Q4 2023, filed 15 Feb 2024.